Duloxetine
Product Images NDC 63629-5202

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 63629-5202). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lbl636295202

Label for Duloxetine DR 60mg Capsule by Bryant Ranch Prepack, comparing to Cymbalta 60mg Capsule from Sun Pharma Global FZE. The label includes storage instructions at 20°-25°C, a warning about potential drowsiness, lot number 1523487, and a barcode with NDC 63629-5202.*

FDA Label Image

Spl Duloxetine Figure1

A line graph showing the proportion of patients with relapse over time from randomization (in days). The graph compares two groups: Placebo and Duloxetine treatment, with the Duloxetine group showing a lower proportion of relapse over time. The x-axis represents days from randomization to relapse, and the y-axis represents the proportion of patients with relapse.*

FDA Label Image

Spl Duloxetine Figure10

A line graph comparing percentage improvement in pain from baseline (x-axis) against the percentage of patients improved (y-axis) between placebo and Duloxetine 60 mg/120 mg once daily. The graph shows two lines representing placebo and Duloxetine treatment groups across varying levels of pain improvement.*

FDA Label Image

Spl Duloxetine Figure2

A line graph showing the proportion of patients with relapse over time from randomization to relapse in days. The chart compares three conditions: Treatment, Placebo, and Duloxetine, with distinct lines representing each group's relapse rates through approximately 280 days.*

FDA Label Image

Spl Duloxetine Figure3

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine at 20 mg QD, 60 mg QD, 60 mg BID, and placebo. It compares the efficacy of different Duloxetine dosages and placebo over the range of pain improvement percentages.*

FDA Label Image

Spl Duloxetine Figure4

A line chart comparing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo groups. The x-axis represents percent improvement in pain from 0 to 100%, and the y-axis shows the percentage of patients improved. The graph shows higher improvement rates for Duloxetine groups compared to placebo.*

FDA Label Image

Spl Duloxetine Figure5

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and Placebo, demonstrating the distribution of pain improvement across different thresholds.*

FDA Label Image

Spl Duloxetine Figure6

A line graph depicting the percentage of patients improved against percent improvement in pain from baseline for Duloxetine at 120 mg, 60 mg, and 20 mg once daily, compared with placebo. The graph shows decreasing patient improvement percentages as percent improvement in pain increases, with all Duloxetine doses trending above placebo.*

FDA Label Image

Spl Duloxetine Figure8

A line graph comparing the percentage of patients improved against percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily versus placebo. The graph shows two lines, one for placebo and one for Duloxetine, with the y-axis representing the percentage of patients improved and the x-axis showing increments of pain improvement percentage from 0 to 100.*

FDA Label Image

Spl Duloxetine Figure9

A line graph showing the percentage of patients improved plotted against percent improvement in pain from baseline. Two curves compare placebo and Duloxetine 60 mg once daily, with Duloxetine showing higher patient improvement percentages across most pain improvement levels.*

FDA Label Image

Spl Duloxetine Structure

Chemical structure of duloxetine hydrochloride as depicted in the image, showing its molecular arrangement including a naphthalene group, a thiophene ring, an ether linkage, and an amine group associated with hydrochloride.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.